Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug-Related Adrs

Predictive ADMET: Integrated Approaches in Drug Discovery and Development

Volumn 9781118299920, Issue , 2014, Pages 23-45

  Kaserer, Teresa ^a   Temml, Veronika ^a   Schuster, Daniela ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Adverse bioactivity profiles; Drug related ADRs; Polypharmacology; Toxicity

Indexed keywords

BIOACTIVITY; FORECASTING; PHARMACOKINETICS; WELL TESTING;

ADVERSE BIOACTIVITY PROFILE; DRUG EFFECTS; DRUG-RELATED ADR; ESTIMATION AND PREDICTIONS; MECHANISM-BASED; PHARMACOKINETIC PROPERTIES; POLYPHARMACOLOGY; PROPERTY; TARGET BINDING; TOXICOLOGICAL PROPERTIES;

TOXICITY;

EID: 84926399500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118783344.ch2     Document Type: Chapter

References (115)

1. Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., Schacht, A.L. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203-214.
2. Kola, I., Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates?. Nature Reviews Drug Discovery, 3, 711-715.
3. Schuster, D., Laggner, C., Langer, T. (2005). Why drugs fail-a study on side effects in new chemical entities. Current Pharmaceutical Design, 11, 3545-3559.
4. Wang, J., Skolnik, S. (2009). Recent advances in physicochemical and ADMET profiling in drug discovery. Chemistry & Biodiversity, 6, 1887-1899.
5. Wang, J., Urban, L., Bojanic, D. (2007). Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opinion on Drug Metabolism & Toxicology, 3, 641-665.
6. Mestres, J., Gregori-Puigjané, E., Valverde, S., Solé, R.V. (2009). The topology of drugtarget interaction networks: Implicit dependence on drug properties and target families. Molecular Biosystems, 5, 1051-1057.
7. Petrelli, A., Giordano, S. (2008). From single- to multi-target drugs in cancer therapy:When aspecificity becomes an advantage. Current Medicinal Chemistry, 15, 422-432.
8. Knight, Z.A., Lin, H., Shokat, K.M. (2010). Targeting the cancer kinome through polypharmacology. Nature Reviews: Cancer, 10, 130-137.
9. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., Drewes, G. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotechnology, 25, 1035-1044.
10. Hopkins, A.L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4, 682-690.
11. Wermuth, C.G. (2006). Selective optimization of side activities: The SOSA approach. Drug Discovery Today, 11, 160-164.
12. Wang, X., Douglas, S.D., Lai, J.P., Tuluc, F., Tebas, P., Ho, W.Z. (2007). Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. Journal of NeuroImmune Pharmacology, 2, 42-48.
13. Manak, M.M., Moshkoff, D.A., Nguyen, L.T., Meshki, J., Tebas, P., Tuluc, F., Douglas, S.D. (2010). Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS, 24, 2789-2796.
14. Shim, J.S., Matsui, Y., Bhat, S., Nacev, B.A., Xu, J., Bhang, H.E., Dhara, S., Han, K.C., Chong, C.R., Pomper, M.G., So, A., Liu, J.O. (2010). Effect of nitroxoline on angiogenesis and growth of human bladder cancer. Journal of the National Cancer Institute, 102, 1855-1873.
15. World Health Organization (WHO), Use of thalidomide in leprosy. http://www. who.int/lep/research/thalidomide/en/index.html last accessed 10-02-2012.
16. European Medicines Agency (EMEA), http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Summary_for_the_public/human/000823/WC500037052.pdf last accessed 10-02-2012.
17. National Cancer Institute (NCI), http://www.cancer.gov/cancertopics/druginfo/fdathalidomide last accessed 10-02-2012.
18. Pang, K.S. (2003). Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metabolism and Disposition, 31, 1507-1519.
19. van de Waterbeemd, H., Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise?. Nature Reviews: Drug Discovery, 2, 192-204.
20. Leo, A., Hansch, C., Elkins, D. (1971). Partition coefficients and their uses. Chemical Reviews, 71, 525-616.
21. Avdeef, A., Voloboy, D., Foreman, A. Dissolution and solubility, in B. Testa and H. Van de Waterbeemd (eds.), Comprehensive Medicinal Chemistry II, Elsevier, Oxford, UK, 2007, pp. 399-423.
22. Kerns, E.H., Di, L., Carter, G.T. (2008). In vitro solubility assays in drug discovery. Current Drug Metabolism, 9, 879-885.
23. Hidalgo, I.J., Raub, T.J., Borchardt, R.T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96, 736-749.
24. Shah, P., Jogani, V., Bagchi, T., Misra, A. (2006). Role of Caco-2 cell monolayers in prediction of intestinal drug absorption. Biotechnology Progress, 22, 186-198.
25. Kansy, M., Senner, F., Gubernator, K. (1998). Physicochemical high throughput screening:Parallel artificial membrane permeation assay in the description of passive absorption processes. Journal of Medicinal Chemistry, 41, 1007-1010.
26. Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer,V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa,T.,Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-Gliszczynski, M.J., Zhang, L., Consortium, I.T. (2010). Membrane transporters in drug development. Nature Reviews Drug Discovery, 9, 215-236.
27. European Medicines Agency (EMA), Guideline on the Investigation of Drug Interactions. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/ WC500090112.pdf last accessed 09-26-2012.
28. (FDA), F. a. D. A., Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmlast accessed 09-29-2012.
29. Barton, P., Austin, R.P., Fessey, R.E. In vitro models for plasma binding and tissue storage, in B. Testa, H. Van de Waterbeemd (eds.), Comprehensive Medicinal Chemistry II, Elsevier, Oxford, UK, 2007, pp. 21-340.
30. Vuignier, K., Schappler, J., Veuthey, J.L., Carrupt, P.A., Martel, S. (2010). Drug-protein binding: A critical review of analytical tools. Analytical and Bioanalytical Chemistry, 398, 53-66.
31. Duffus, J.H., Nordberg, M., Templeton, D.M. (2007). Glossary of terms used in toxicology, 2nd ed. (IUPAC Recommendations 2007). 79, 1153-1344.
32. Singh, D., Kashyap, A., Pandey, R.V., Saini, K.S. (2011). Novel advances in cytochrome P450 research. Drug Discovery Today, 16, 793-799.
33. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moore, J.T., Kliewer, S.A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. Journal of Clinical Investigation, 102, 1016-1023.
34. Moore, L.B., Goodwin, B., Jones, S.A.,Wisely, G.B., Serabjit-Singh, C.J.,Willson, T.M., Collins, J.L., Kliewer, S.A. (2000). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proceedings of the National Academy of Sciences U S A, 97, 7500-7502.
35. Lin, J.H. (2006). CYP induction-mediated drug interactions: In vitro assessment and clinical implications. Pharmaceutical Research, 23, 1089-1116.
36. Fowler, S., Zhang, H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: Current status on methodologies and their utility for predicting drug-drug interactions. The AAPS Journal, 10, 410-424.
37. Kiani, J., Imam, S. Z. (2007). Medicinal importance of grapefruit juice and its interaction with various drugs. Nutrition Journal, 6, 33.
38. Houck, K.A., Kavlock, R.J. (2008). Understanding mechanisms of toxicity: Insights from drug discovery research. Toxicology and Applied Pharmacology, 227, 163-178.
39. Ames, B.N., Mccann, J., Yamasaki, E. (1975). Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Research, 31, 347-364.
40. Clive, D., Spector, J. F. (1975). Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y mouse lymphoma cells. Mutation Research, 31, 17-29.
41. Kirsch-Volders, M., Elhajouji, A., Cundari, E., Van Hummelen, P. (1997). The in vitro micronucleus test: A multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutation Research, 392, 19-30.
42. Sanguinetti, M.C., Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, 440, 463-469.
43. Roth, B.L. (2007). Drugs and valvular heart disease. New England Journal of Medicine, 356, 6-9.
44. Schuster, D., Kowalik, D., Kirchmair, J., Laggner, C., Markt, P., Aebischer-Gumy, C., Ströhle, F., Möller, G., Wolber, G., Wilckens, T., Langer, T., Odermatt, A., Adamski, J. (2011). Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening. Journal of Steroid Biochemistry and Molecular Biology, 125, 148-161.
45. Nashev, L.G., Schuster, D., Laggner, C., Sodha, S., Langer, T., Wolber, G., Odermatt, A. (2010). The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3:Virtual screening as a strategy to identify potential endocrine disrupting chemicals. Biochemical Pharmacology, 79, 1189-1199.
46. Nashev, L.G., Vuorinen, A., Praxmarer, L., Chantong, B., Cereghetti, D., Winiger, R., Schuster, D., Odermatt, A. (2012). Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action. PLoS ONE, 7, e46958.
47. Clere, N., Lauret, E., Malthiery, Y., Andriantsitohaina, R., Faure, S. (2012). Estrogen receptor alpha as a key target of organochlorines to promote angiogenesis. Angiogenesis, 15, 745-760.
48. Hao, C.J., Cheng, X.J., Xia, H.F., Ma, X. (2012). The endocrine disruptor diethylstilbestrol induces adipocyte differentiation and promotes obesity in mice. Toxicology and Applied Pharmacology, 263, 102-110.
49. Wu, C.Y., Benet, L.Z. (2005). Predicting drug disposition via application of BCS: Transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research, 22, 11-23.
50. Watanabe, T., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H., Sugiyama, Y. (2009). Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metabolism and Disposition, 37, 1471-1479.
51. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25.
52. Gasteiger, J. (2006). Of molecules and humans. Journal of Medicinal Chemistry, 49, 6429-6434.
53. Keiser, M.J., Roth, B.L., Armbruster, B.N., Ernsberger, P., Irwin, J.J., Shoichet, B.K. (2007). Relating protein pharmacology by ligand chemistry. Nature Biotechnology, 25, 197-206.
54. Kier, L.B.MOTheory in Drug Research, Academic Press. New York, 1971, pp. 164-169.
55. Rester, U. (2008). From virtuality to reality - Virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective. Current Opinion on Drug Discovery and Development, 11, 559-568.
56. Puzyn, T., Rasulev, B., Gajewicz, A., Hu, X., Dasari, T.P., Michalkova, A., Hwang, H.M., Toropov, A., Leszczynska, D., Leszczynski, J. (2011). Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. Nature Nanotechnology, 6, 175-178.
57. Lather,V., Fernandes, M.X. (2011). ComparativeQSARanalyses of competitiveCYP2C9 inhibitors using three-dimensional molecular descriptors. Chemical Biology & Drug Design, 78, 112-123.
58. Verma, J., Khedkar, V.M., Coutinho, E.C. (2010). 3D-QSAR in drug design-a review. Current Topics in Medicinal Chemistry, 10, 95-115.
59. Salum, L.B., Andricopulo, A.D. (2009). Fragment-based QSAR: Perspectives in drug design. Molecular Diversity, 13, 277-285.
60. Rabal, O., Oyarzabal, J. (2012). Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space. Journal of Chemical Information and Modeling, 52, 1086-1102.
61. Lounkine, E., Keiser, M.J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A.K., Ĉoté, S., Shoichet, B.K., Urban, L. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature, 486, 361-367.
62. Poroikov, V., Filimonov, D., Lagunin, A., Gloriozova, T., Zakharov, A. (2007). PASS:Identification of probable targets and mechanisms of toxicity. SAR and QSAR in Environmental Research, 18, 101-110.
63. PASSonline. http://www.pharmaexpert.ru/passonline (accessed 09-20-2012).
64. OSIRIS property Explorer. http://www.organic-chemistry.org/prog/peo/ (accessed 10-04-2012).
65. ADMETpredictor, http://www.simulationsplus.com/Products.aspx?grpID=1&cID=11&pID=13 09-25-2012.
66. Crivori, P., Cruciani, G., Carrupt, P.A., Testa, B. (2000). Predicting blood-brain barrier permeation from three-dimensional molecular structure. Journal of Medicinal Chemistry, 43, 2204-2216.
67. ADRIANA.Code, Molecular Networks GmbH, Erlangen, Germany, http://www. molecular-networks.com/products/adrianacode 09-25-2012.
68. SONNIA-Self-Organizing Neural Network Package, Molecular Networks GmbH, Erlangen, Germany, http://www.molecular-networks.com/products/sonnia 09-25-2012.
69. Wermuth, C.G., Ganellin, C.R., Lindberg, P., Mitscher, L.A. (1998). Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure and Applied Chemistry, 70, 1129-1143.
70. Wolber, G., Langer, T. (2005). LigandScout: 3-D pharmacophores derived from proteinbound ligands and their use as virtual screening filters. Journal of Chemical Information and Modeling, 45, 160-169.
71. Discovery Studio, Accelrys Inc., San Diego, CA, USA http://accelrys.com/products/discovery-studio/ 10-02-2012.
72. Dixon, S.L., Smondyrev, A.M., Rao, S.N. (2006). PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chemical Biology & Drug Design, 67, 370-372.
73. Rush, T.S., Grant, J.A., Mosyak, L., Nicholls, A. (2005). A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. Journal of Medicinal Chemistry, 48, 1489-1495.
74. Waltenberger, B., Schuster, D., Paramapojn, S., Gritsanapan, W., Wolber, G., Rollinger, J.M., Stuppner, H. (2011). Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part II: Identification of enzyme inhibitors from Prasaplai, a Thai traditional medicine. Phytomedicine, 18, 119-133.
75. Duwensee, K., Schwaiger, S., Tancevski, I., Eller, K., van Eck, M., Markt, P., Linder, T., Stanzl, U., Ritsch, A., Patsch, J.R., Schuster, D., Stuppner, H., Bernhard, D., Eller, P. (2011). Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein. Atherosclerosis, 219, 109-115.
76. HypoDB. Inte:Ligand GmbH, Maria Enzersdorf, Austria, 2006-2012 http://www. inteligand.com/pharmdb/, last accessed 10-05-2012.
77. Liu, X., Ouyang, S., Yu, B., Liu, Y., Huang, K., Gong, J., Zheng, S., Li, Z., Li, H., Jiang, H. (2010). PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Research, 38, W609-614.
78. Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry, 19, 1639-1662.
79. Gold, CCDC, Cambridge, UK, http://www.ccdc.cam.ac.uk/products/life_sciences/gold/ last accessed 10-02-2012.
80. Sousa, S.F., Fernandes, P.A., Ramos, M.J. (2006). Protein-ligand docking: current status and future challenges. Proteins, 65, 15-26.
81. Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D. T., Repasky, M.P., Knoll, E.H., Shelley, M., Perry, J.K., Shaw, D.E., Francis, P., Shenkin, P.S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47, 1739-1749.
82. Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A.I., Hufeisen, S.J., Jensen, N.H., Kuijer, M.B., Matos, R.C., Tran, T.B., Whaley, R., Glennon, R.A., Hert, J., Thomas, K.L., Edwards, D.D., Shoichet, B.K., Roth, B.L. (2009). Predicting new molecular targets for known drugs. Nature, 462, 175-181.
83. Zheng, X., Ekins, S., Raufman, J.P., Polli, J.E. (2009). Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Molecular Pharmaceutics, 6, 1591-1603.
84. Tarcsay, A., Kiss, R., Keseru, G.M. (2010). Site of metabolism prediction on cytochrome P450 2C9:Aknowledge-based docking approach. Journal of Computer-Aided Molecular Design, 24, 399-408.
85. Deeb, O., Rosales-Hernández, M.C., Gómez-Castro, C., Garduño-Juárez, R., Correa-Basurto, J. (2010). Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. Biopolymers, 93, 161-170.
86. Carlsson, L., Spjuth, O., Adams, S., Glen, R.C., Boyer, S. (2010). Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse. BMC Bioinformatics, 11, 362.
87. Rydberg, P., Gloriam, D.E., Zaretzki, J., Breneman, C., Olsen, L. (2010). SMARTCyp: A 2D method for prediction of Cytochrome P450-mediated drug metabolism. ACS Medicinal Chemistry Letters, 1, 96-100.
88. Zhang, J., Pan, X., Wang, C., Wang, F., Li, P., Xu, W., He, L. (2012). Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors. Chemical Biology & Drug Design, 79, 353-359.
89. Steindl, T.M., Schuster, D., Laggner, C., Chuang, K., Hoffmann, R.D., Langer, T. (2007). Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models. Journal of Chemical Information and Modeling, 47, 563-571.
90. Yadav, D.K., Khan, F., Negi, A.S. (2012). Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. Journal of Molecular Modeling, 18, 2513-2525.
91. (2012) News in brief: Network pharmacology moves into the clinic. Nature Reviews:Drug Discovery, 11, 589.
92. Schuster, D., Laggner, C., Steindl, T.M., Langer, T. (2006). Development and validation of an in silico P450 profiler based on pharmacophore models. Current Drug Discovery Technologies, 3, 1-48.
93. Du-Cuny, L., Chen, L., Zhang, S. (2011). A critical assessment of combined ligand- and structure-based approaches to hERG channel blocker modeling. Journal of Chemical Information and Modeling, 51, 2948-2960.
94. Schuster, D., Langer, T. (2005). The identification of ligand features essential for PXR activation by pharmacophore modeling. Journal of Chemical Information and Modeling, 45, 431-439.
95. Stockner, T., de Vries, S.J., Bonvin, A.M., Ecker, G.F., Chiba, P. (2009). Data-driven homology modelling of P-glycoprotein in the ATP-bound state indicates flexibility of the transmembrane domains. FEBS Journal, 276, 964-972.
96. Dybdahl, M., Nikolov, N.G.,Wedebye, E.B., Jónsdóttir, S., Niemelä, J.R. (2012). QSAR model for human pregnane X receptor (PXR) binding: Screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity. Toxicology and Applied Pharmacology, 262, 301-309.
97. Moroy, G., Martiny, V.Y., Vayer, P., Villoutreix, B.O., Miteva, M.A. (2012). Toward in silico structure-based ADMET prediction in drug discovery. Drug Discovery Today, 17, 44-55.
98. Kitchen, D.B., Decornez, H., Furr, J.R., Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews: Drug Discovery, 3, 935-949.
99. Dearden, J.C. (2007). In silico prediction of ADMET properties: How far have we come?. Expert Opinion on Drug Metabolism & Toxicology, 3, 635-639.
100. von Grafenstein, S., Mihaly-Bison, J., Wolber, G., Bochkov, V.N., Liedl, K.R., Schuster, D. (2012). Identification of novel liver X receptor activators by structure-based modeling. Journal of Chemical Information and Modeling, 52, 1391-1400.
101. Sato, T., Yuki, H., Takaya, D., Sasaki, S., Tanaka, A., Honma, T. (2012). Application of support vector machine to three-dimensional shape-based virtual screening using comprehensive three-dimensional molecular shape overlay with known inhibitors. Journal of Chemical Information and Modeling, 52, 1015-1026.
102. Schuster, D. (2010). 3D pharmacophores as tools for activity profiling. Drug Discovery Today: Technologies, 7, 205-211.
103. Allen, J.A., Roth, B.L. (2011). Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annual Reviews of Pharmacology and Toxicology, 51, 117-144.
104. Bajorath, J. (2002). Integration of virtual and high-throughput screening. Nature Reviews:Drug Discovery, 1, 882-894.
105. Guido, R.V., Oliva, G., Andricopulo, A.D. (2011). Modern drug discovery technologies:Opportunities and challenges in lead discovery. Combinatorial Chemistry and High Throughput Screening, 14, 830-839.
106. López-Vallejo, F., Caulfield, T., Martí{dotless}nez-Mayorga, K., Giulianotti, M.A., Nefzi, A., Houghten, R.A., Medina-Franco, J.L. (2011). Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. Combinatorial Chemistry and High Throughput Screening, 14, 475-487.
107. Babaoglu, K., Simeonov, A., Irwin, J.J., Nelson, M.E., Feng, B., Thomas, C.J., Cancian, L., Costi, M.P., Maltby, D.A., Jadhav, A., Inglese, J., Austin, C.P., Shoichet, B. K. (2008). Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. Journal of Medicinal Chemistry, 51, 2502-2511.
108. Gleeson, M.P., Hersey, A., Hannongbua, S. (2011). In-silico ADME models: A general assessment of their utility in drug discovery applications. Current Topics in Medicinal Chemistry, 11, 358-381.
109. Schuster, D., Spetea, M., Music, M., Rief, S., Fink, M., Kirchmair, J., Schütz, J.,Wolber, G., Langer, T., Stuppner, H., Schmidhammer, H., Rollinger, J.M. (2010). Morphinans and isoquinolines: Acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors. Bioorganic & Medicinal Chemistry, 18, 5071-5080.
110. Doman, T.N., McGovern, S.L., Witherbee, B.J., Kasten, T.P., Kurumbail, R., Stallings, W.C., Connolly, D.T., Shoichet, B.K. (2002). Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. Journal of Medicinal Chemistry, 45, 2213-2221.
111. Wienkers, L.C., Heath, T.G. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews: Drug Discovery, 4, 825-833.
112. Xie, L., Bourne, P.E. (2011). Structure-based systems biology for analyzing off-target binding. Current Opinion in Structural Biology, 21, 189-199.
113. Merino, A., Bronowska, A.K., Jackson, D.B., Cahill, D.J. (2010). Drug profiling: Knowing where it hits. Drug Discovery Today, 15, 749-756.
114. Brown, J.B., Okuno, Y. (2012). Systems biology and systems chemistry: New directions for drug discovery. Chemistry & Biology, 19, 23-28.
115. Wang, J., Collis, A. (2011). Maximizing the outcome of earlyADMETmodels: Strategies to win the drug-hunting battles?. Expert Opinion on Drug Metabolism & Toxicology, 7, 381-386.